Finnish healthtech startup Adamant Health teams up with German medtech company Gerresheimer to improve the care for people with Parkinson's disease.
Adamant Health鈥檚 technology, using electromyography, is the first one in the world to reliably measure the impact of medication in patients' motor symptoms, also outside clinic visits, in daily life. Medical doctors can use the technology to decide on more targeted medication, and further, pharma companies can develop better medicine as they now can get real data from the field.
German medtech company Gerresheimer invests in Finnish startup to enable measurements in day-to-day life of people suffering from Parkinson鈥檚 disease. Adamant Health and Gerresheimer have great strategic synergies in bringing new and revolutionary solutions to provide better days for people with Parkinson鈥檚 disease. Adamant Health secures funding for further developing their Parkinson鈥檚 disease Measurement and Analysis Service and entering new markets. In addition to Gerresheimer, existing investors Voima Ventures and Cor Group, together with several angel investors, are participating in the round.
鈥淲ith this funding, we鈥檙e ensuring Adamant Health鈥檚 solution鈥檚 further development and our ability to bring it into new markets. Our Measurement and Analysis Service 鈥 including the CE marked analysis technology 鈥 aims to improve the daily life of people with Parkinson鈥檚 disease. The service enables physicians to individualize their treatment based on detailed visibility on their patient鈥檚 symptoms and overall situation鈥 said Paulus Carpelan, CEO, Adamant Health Ltd. 鈥淲e are excited, and we鈥檙e looking forward to collaborating with Gerresheimer towards our joint vision of improving healthcare outcomes for people with Parkinson鈥檚 disease鈥 he continued.
Adamant Health鈥檚 analysis technology uses data from a wearable electromyography (EMG) and motion sensor to provide long-term accurate visibility to motor symptoms typical in Parkinson鈥檚 disease. Adamant Health is the only provider in the world of this kind of technology, which can be used in clinical patient care at clinics, as well as at home.
鈥淲e see great opportunities in our partnership with Adamant Health. Our common goal is to optimize the personalized treatment of Parkinson鈥檚 disease and to improve the patient鈥檚 quality of life dramatically,鈥 said Dietmar Siemssen, CEO of Gerresheimer AG. 鈥淥ur investment will help drive the further development of Adamants unique technology and service. At the same time, it is part of our strategic expansion into innovative, platform-based drug delivery devices and digital disease monitoring鈥, he added.
To date, Adamant Health has raised 2,2M鈧 for its seed round in total, and is still looking for 800k鈧 to complete the round. With the investment, the Adamant Health team are able to continue working towards their end goal - that the technology becomes widely used throughout Parkinson鈥檚 care, research and pharma companies for the benefit of everyone suffering from Parkinson鈥檚 disease.
Contacts:
Adamant Health Ltd Paulus Carpelan CEO Adamant Health +358 50 486 7516 paulus@adamanthealth.com
Gerresheimer AG Contact Press Ueli Utzinger Group Senior Director Marketing & Communication T +49 211 6181-250 ueli.utzinger@gerresheimer.com
Contact Investor Relations Carolin Nadilo Corporate Senior Director Investor Relations T +49 211 6181-220 carolin.nadilo@gerresheimer.com About
Adamant Health
Adamant Health Ltd. is a research innovation based health technology company focusing on developing and providing measurement and analysis services for Parkinson鈥檚 disease and other movement disorders. The novel technology is based on over 15 years of research and clinical tests done at the 91天美. Adamant Health鈥檚 mission is to bring the research findings for the benefit of people with movement disorders by enabling clinicians, pharma companies and researchers to base their work on objective and detailed real-world patient data measured as part of patients鈥 daily life. https://www.adamanthealth.com/
About Gerresheimer
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centres in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generated annual revenues in 2021 of around EUR1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being. www.gerresheimer.com
